<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602314</url>
  </required_header>
  <id_info>
    <org_study_id>CML1415</org_study_id>
    <nct_id>NCT02602314</nct_id>
  </id_info>
  <brief_title>Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia</brief_title>
  <acronym>SUSTRENIM</acronym>
  <official_title>Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline
      therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined
      by the ELN criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, interventional, randomized, two arms, phase IV study evaluating both
      the depth of the molecular response and the rate of treatment free remission rate in newly
      diagnosed CP-CML patients treated with NIL or IM followed by switch to NIL in absence of
      optimal response (defined according the ELN 2013 criteria) as per clinical practice.

      The enrolled patients will be randomized 1:1 between NIL and IM. Patients will be stratified
      according to the Sokal risk score to high versus intermediate/low risk groups. Newly
      diagnosed patients will be treated according to the registered dose of NIL and IM for
      frontline chronic phase CML (300 mg BID and 400 mg OAD, respectively). The patients
      intolerant to IM and the patients without optimal response to IM at 3 months, at 6 months, at
      12 months (except the patients with progression to accelerated or blastic phase) will be
      switched to NIL second line.

      The absence of optimal response is defined by at least one of the following ELN criteria: a)
      Absence of Complete Hematologic Response at 3 months or thereafter; b) Absence of Partial
      Cytogenetic Response (&gt; 35% Ph+ metaphases) at 3 months; c) BCR-ABL transcript level &gt; 10%
      according to the IS at 3 months; d) Absence of Complete Cytogenetic Response (&gt; 1% Ph+
      metaphases) at 6 months; e) BCR-ABL transcript level &gt; 1% according to the IS at 6 months; f)
      Absence of Major Molecular Response (MR3.0, transcript level &gt; 0.1% according to the IS) at
      12 months.

      Treatment choice for the patients with progression to advanced disease phase while on IM and
      for the patients intolerant to or resistant (including progressions to advanced phases) to
      NIL will be up to the principal investigator of the participating Center. However,
      information concerning the course and outcome of these patients will be collected and
      recorded for at least 5 years, and they could be enrolled in investigational studies promoted
      by GIMEMA or other sponsors.

      After the induction of deep molecular remission phase of therapy, i.e. the first two years of
      the study, residual disease will be closely monitored (quarterly) by Q-PCR assays. All the
      patients who obtain a reduction greater than 4.0 logs of residual disease (MR4.0) within the
      first three years of treatment, and maintain this level of response in all the subsequent
      tests up to the end of the fourth years of therapy qualify for the discontinuation phase of
      the study. Therefore, all patients who are in MR4.0 after a four-year period of TKI
      treatment, that must include in its final part at least one years of maintained MR4.0,
      defined as 12-month period during which the MR4.0 never is lost in 4 consecutive MRD analyses
      at three-monthly intervals, will enter the treatment free remission (TFR) phase of the study.
      In case of loss of MR3.0, the last assumed TKI will be resumed at the same dose.

      All patients, including those who do not match the criteria for discontinuation of TKI
      treatment, will continue the assigned treatment and will be followed for 5 years, starting
      from the date of enrolment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2016</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of of patients with molecular response</measure>
    <time_frame>At 24 months from study entry</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who remain in sustained treatment free remission, without molecular relapse</measure>
    <time_frame>After 12 months after entering the treatment-free-remission (TFR) phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with molecular response</measure>
    <time_frame>4 years after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patiens in progression-free survival</measure>
    <time_frame>5 years after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with major molecular response</measure>
    <time_frame>At 1, 2, 3 and 4 years from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of toxic events</measure>
    <time_frame>At 5 years from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who discontinue treatment</measure>
    <time_frame>At 5 years from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with quality of life differences between treatment arms over time</measure>
    <time_frame>At baseline and at 3, 6, 12, 18, 24, 30, 36, 42, 48, and 60 months from study entry.</time_frame>
    <description>To assess the patient-reported quality of life (QoL) and adherence to therapy at baseline and at 6, 12, 18, 24, 27, 33, 36, 39, 42, 48, 51, 54 and 60 months in the following QoL scales: Fatigue, Physical Functioning and Global Health Status/QoL (outcome measure: EORTC QLQ-C30), Impact on Daily Life and Symptom Burden (outcome measure: EORTC CML-24), Burden of Illness (outcome measure: EORTC QLQ-ELD14).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Chronyc Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Imatinib + Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <arm_group_label>Imatinib + Nilotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <arm_group_label>Imatinib + Nilotinib</arm_group_label>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a confirmed diagnosis of BCR/ABL+ CML in chronic phase

        Documented chronic phase CML must meet all the following criteria:

        &lt; 15% blasts in peripheral blood &lt; 30% blasts plus promyelocytes in peripheral blood &lt; 20%
        basophils in the peripheral blood

          -  100 x 109/L (≥ 100,000/mm3) platelets

               -  Age ≥18

               -  ECOG performance status of 0-2

               -  Evidence of typical BCR-ABL transcripts which are amenable to standardized RQ-PCR

               -  Adequate end organ function as defined by:

        Total bilirubin &lt; 1.5 x ULN (ULN = upper limit of normal in a local institution lab).

        Does not apply to patients with isolated hyperbilirubinemia (e.g., Gilbert's disease) grade
        &lt; 3 SGOT (AST) and SGPT (ALT) ≤ 3 x ULN Serum amylase and lipase ≤ 2 x ULN Alkaline
        phosphatase ≤ 2.5 x ULN Serum creatinine &lt; 1.5 x ULN

          -  Having completed the QoL baseline evaluation (i.e., before randomization)

          -  Written informed consent prior to any study procedures.

        Exclusion Criteria:

          -  Expression of any atypical BCR-ABL transcripts, instead of the classical P210-encoding
             type with the e13a2 or the e14a2 junction at screening.

          -  Previous treatment with BCR-ABL inhibitors for a period longer than 1 month.

          -  Previous anticancer agents (hydroxyurea, anagrelide, interferon) for CML for a time
             longer than three months.

          -  Poorly controlled diabetes mellitus (defined as HbA1c &gt;8%).

          -  Prior documented history of coronary heart disease, including myocardial infarction,
             coronary bypass, coronary stent, and symptomatic angina:

        LVEF &lt;45% or below the institutional lower limit of the normal range (whichever ishigher)
        Complete left bundle branch block Right bundle branch block plus left anterior or posterior
        hemiblock Use of a ventricular-paced pacemaker Congenital long QT syndrome or a known
        family history of long QT syndrome History of or presence of clinically significant
        ventricular or atrial tachyarrhythmias

          -  Atrial fibrillation or flutter

          -  Clinically significant resting bradycardia (&lt; 50 beats per minute)

          -  QTc &gt; 450 msec on the average of three serial screening ECGs (using the QTcF formula).
             If QTcF &gt; 450 msec and electrolytes are not within normal ranges, electrolytes should
             be corrected and the patient re-tested History or clinical signs of myocardial
             infarction within 12 months of study entry History of unstable angina within 12 months
             of study entry Other clinically significant heart disease (e.g. congestive heart
             failure)

               -  Uncontrolled hypertension is not a heart disease.

               -  History of peripheral arterial occlusive disease.

               -  History of acute pancreatitis within 12 months of study entry, or a past medical
                  history of chronic pancreatitis.

               -  Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers
                  which cannot be either discontinued or switched to a different medication prior
                  to starting study drug.

               -  Patients who are currently receiving treatment with any medications that have the
                  potential to prolong the QT interval and for which cannot be either safely
                  discontinued or switched to a different medication prior to starting study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrizio Pane</last_name>
    <role>Study Chair</role>
    <affiliation>Università Federico II of Naples</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Pini</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Pini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federico Monaco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi G. Salesi</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Rupoli</last_name>
    </contact>
    <investigator>
      <last_name>Serena Rupoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Rita Scortecchini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az.Ospedaliera S.G.Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fausto Palmieri</last_name>
    </contact>
    <investigator>
      <last_name>Fausto Palmieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raffaele Palmieri</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgina Specchia</last_name>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Russo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Torre 6 piano 4 - ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Rambaldi</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulia Quaresmini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianantonio Rosti</last_name>
    </contact>
    <investigator>
      <last_name>Gianantonio Rosti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriele Gugliotta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Domenico Russo</last_name>
    </contact>
    <investigator>
      <last_name>Domenico Russo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Malagola</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL N.8 -Ospedale A. Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Usala</last_name>
    </contact>
    <investigator>
      <last_name>Emilio Usala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Di Raimondo</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio Stagno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Medicina Interna - ASUR Marche 8 - Ospedale Civile</name>
      <address>
        <city>Civitanova Marche</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riccardo Centurione</last_name>
    </contact>
    <investigator>
      <last_name>Riccardo Centurione</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacopo Olivieri</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Cavazzini</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Cavazzini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Lista</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia ASO S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Rapezzi</last_name>
    </contact>
    <investigator>
      <last_name>Davide Rapezzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Sorasio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonella Gozzini</last_name>
    </contact>
    <investigator>
      <last_name>Antonella Gozzini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Scappini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST.Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Gobbi</last_name>
    </contact>
    <investigator>
      <last_name>Marco Gobbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micaela Bergamaschi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Reddiconto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Musolino</last_name>
    </contact>
    <investigator>
      <last_name>Caterina Musolino</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabina Russo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia- Ospedale dell'Angelo - Mestre</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Bassan</last_name>
    </contact>
    <investigator>
      <last_name>Renato Bassan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosaria Sancetta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Marasca</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Marasca</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanna Leonardi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Annunziata</last_name>
    </contact>
    <investigator>
      <last_name>Mario Annunziata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Pane</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Mastrullo</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Mastrullo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rosaria Esposito</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monia Lunghi</last_name>
    </contact>
    <investigator>
      <last_name>Monia Lunghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. CTMO Ematologia - Osp. S. Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Murgia</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Murgia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Monne</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanna Rege</last_name>
    </contact>
    <investigator>
      <last_name>Giovanna Rege</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Fava</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Fabbiano</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Fabbiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Malato</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Siragusa</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Siragusa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia di Muraglia - CTMO Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Visani</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Visani</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Barulli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Vallisa</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Vallisa</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Trabacchi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az.Ospedaliera S.G.Moscati</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Pizzuti</last_name>
    </contact>
    <investigator>
      <last_name>Michele Pizzuti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Matturro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Salvucci</last_name>
    </contact>
    <investigator>
      <last_name>Maria Salvucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Zanchini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Martino</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Martino</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caterina Alati</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Avanzini</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Avanzini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabella Capodanno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agostino Tafuri</last_name>
    </contact>
    <investigator>
      <last_name>Agostino Tafuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Montefusco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia - Università Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianna De Muro</last_name>
    </contact>
    <investigator>
      <last_name>Marianna De Muro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Sica</last_name>
    </contact>
    <investigator>
      <last_name>Simona Sica</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federica Sorà</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma &quot;Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Breccia</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Breccia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuliana Alimena</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S. Eugenio</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Abruzzese</last_name>
    </contact>
    <investigator>
      <last_name>Elisabetta Abruzzese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncologia Giovanni Paolo II &quot;Vito Fazzi&quot;</name>
      <address>
        <city>Rossano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Iuliano</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Iuliano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Aquila Santoro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Sgherza</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Fozza</last_name>
    </contact>
    <investigator>
      <last_name>Claudio Fozza</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Longu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati</last_name>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debora Luzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica-Centro Trapianti e Terapie cellulari Azienda Ospedaliero-Universitaria, Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro Tiribelli</last_name>
    </contact>
    <investigator>
      <last_name>Mauro Tiribelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federico De Marchi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimiliano Bonifacio</last_name>
    </contact>
    <investigator>
      <last_name>Massimiliano Bonifacio</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigi Scaffidi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS N.6 Osp. S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eros Di Bona</last_name>
    </contact>
    <investigator>
      <last_name>Eros Di Bona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>Imatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

